Today: 28 June 2026
Browse Category

Biotechnology 17 December 2025 - 26 December 2025

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab shares were indicated around $18.58 premarket Friday, valuing the company near $2.1 billion. China approved COBENFY for schizophrenia on December 23, adding to recent company catalysts. U.S. markets reopen for a full session after the Christmas holiday, with thin liquidity and wider spreads expected. ZLAB’s 52-week range spans $16.82 to $44.34, with momentum indicators near oversold levels.
26 December 2025
···
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics shares closed at $27.38 on December 24, up 26% after the company reported a favorable interim safety update for its EDG-7500 therapy in hypertrophic cardiomyopathy. Pre-market trading showed the stock at $27.46 as of 8:52 a.m. ET Friday. No clinically meaningful drops in ejection fraction or new atrial fibrillation were seen in the latest trial cohort. Regular U.S. trading resumes at 9:30 a.m. ET.
26 December 2025
···
Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly shares closed up 0.50% at $1,076.98 in light Christmas Eve trading, then slipped to $1,071.74 after hours amid thin volume. The move followed news that U.S. regulators plan to expand Medicaid and Medicare coverage for GLP‑1 obesity drugs, including Lilly’s Zepbound, with a $50 monthly cap for Medicare starting January 2027.
24 December 2025
···
Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences shares traded around $18.1–$18.5 on December 24, 2025, holding gains after positive WVE-007 obesity data and a recent capital raise. No new company news crossed the wire, but analysts raised fair value targets following the Phase 1 results showing reduced visceral fat and increased lean mass. At least one after-hours trade printed below the regular close amid thin holiday volume.
24 December 2025
··
Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings (RGC) surged 14% to $25.25 on Dec. 24, 2025, despite remaining a pre-revenue company. The move followed a ValueWalk article highlighting RGC’s 17,000% gain in 2025, driven by low float, momentum trading, and a recent 38-for-1 stock split. Intraday prices ranged from $22.00 to $26.33. RGC’s market cap neared $11 billion.
24 December 2025
··
Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question

Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question

Indaptus Therapeutics announced a $6 million preferred-stock financing with investor David Lazar, who will become chairman and co-CEO. The deal could add up to 111 million common shares if converted, pending shareholder approval. Shares jumped over 60% after hours on December 23, 2025, following the news, after closing at $1.95 in regular trading. Two directors resigned as part of the boardroom changes.
24 December 2025
··
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna shares fell 7.48% to $32.29 on Dec. 23 after a sharp rally earlier in the week. The drop followed news of up to $54.3 million in CEPI funding for its bird flu vaccine, with a Phase 3 trial set for early 2026. The stock’s volatility contrasted with broader market gains, as investors reacted to recent headlines and year-end trading dynamics.
24 December 2025
··
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics shares traded near $67.50 on Dec. 23, 2025, following strong Phase 2 data for its oral obesity drug aleniglipron, which showed up to 15.3% placebo-adjusted weight loss at 36 weeks. The company also closed a $747.5 million public offering after the trial results.
23 December 2025
····
Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open

Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open

The FDA approved new denosumab biosimilars referencing Amgen’s Prolia and XGEVA after markets closed Monday. Amgen shares ended the day up 1.2% at $331.39. Fitch upgraded Amgen’s credit rating to BBB+ with a stable outlook. Post-market trading showed little immediate reaction.
23 December 2025
···
Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience shares rose about 5.4% to $34.26 midday Dec. 22, 2025, after new licensing deals and product expansions. The stock remains down roughly 26% year-to-date despite the rally. Recent catalysts include a licensing agreement with Aptamer Group for hot-start PCR and NGS products and continued integration with Element Biosciences’ AVITI system. TWST’s 52-week range spans $23.30 to $55.33.
22 December 2025
··
Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion on Dec. 19, paying a 33% premium and adding two rare-disease drugs with $599 million in combined annual sales. The deal, plus an FDA approval for Cytokinetics and new IPO filings, drove biotech stocks higher ahead of the Christmas-shortened trading week. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·····
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics shares surged 20.8% to $25.55 on December 19, 2025, trading over 3.1 million shares after a prior decline. No new company press releases or major updates were issued in the past 24–48 hours. The move followed routine equity grant news on December 2 and Q3 results on November 6. Analyst price targets remain above current levels.
21 December 2025
··
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, offering $14.50 per share. Amicus stock jumped roughly 30% to $14.18 on heavy volume, trading just below the bid as investors assess deal closure risks. Both boards approved the transaction, with closing targeted for Q2 2026 pending shareholder and regulatory approvals.
20 December 2025
·····
Thermo Fisher Scientific Stock (TMO) News Today: What’s Driving Shares, Analyst Forecasts, and Key Catalysts on Dec. 19, 2025

Thermo Fisher Scientific Stock (TMO) News Today: What’s Driving Shares, Analyst Forecasts, and Key Catalysts on Dec. 19, 2025

Thermo Fisher Scientific shares rose 1.27% to $569.54 Friday after the company announced enrollment of the first patient in its PPD CorEvitas Alzheimer’s Disease Registry. The initiative aims to collect global real-world data on Alzheimer’s therapies. Thermo Fisher also opened a new collaboration center for life sciences startups in Philadelphia. Market cap stood near $218 billion.
19 December 2025
··
Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics shares jumped 8.79% to close at $23.01 on Dec. 19 after a volatile session and recent losses. The move coincided with elevated trading volume and options expiration. The company is advancing therapies for muscular dystrophies and cardiac conditions, with key clinical updates expected in late 2025 and beyond.
19 December 2025
···
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical will acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, paying $14.50 per share—a 33% premium to Amicus’ prior close. The transaction, approved by both boards, is expected to close in Q2 2026 pending shareholder and regulatory approvals. BioMarin will fund the deal with cash and $3.7 billion in debt financing. The acquisition adds two rare-disease drugs and a Phase 3 pipeline asset.
19 December 2025
····
Thermo Fisher Scientific (TMO) Stock Today: Alzheimer’s Registry Launch, Analyst Price Targets, and 2026 Catalysts (Dec. 18, 2025)

Thermo Fisher Scientific (TMO) Stock Today: Alzheimer’s Registry Launch, Analyst Price Targets, and 2026 Catalysts (Dec. 18, 2025)

Thermo Fisher Scientific said Thursday it enrolled the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry, aimed at collecting real-world evidence on neurodegenerative care. Shares traded near $561 in the afternoon, down slightly after a 1.33% drop Wednesday. The registry will track long-term safety and effectiveness of Alzheimer’s treatments, including MRI-based monitoring of drug side effects.
18 December 2025
··
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics shares fell 8.8% to $20.35 on Thursday, with no new company news released that day. The stock traded between $20.33 and $22.81 on volume of about 1.25 million shares. EWTX remains 38% below its 52-week high and 92% above its 52-week low. The company’s recent updates include a December stock option grant and a November board appointment.
18 December 2025
··
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed shares fell 16% Thursday after the company said its Phase 2b trial of brensocatib in chronic rhinosinusitis without nasal polyps failed to meet endpoints, prompting it to end development for that indication. The drug’s performance matched or trailed placebo on symptom scores. Insmed reported no new safety issues. The stock traded near $166.75 after hitting a low of $158.06.
18 December 2025
···
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals shares fell 6.61% to A$11.73 on the ASX December 17, with volume at 6.36 million and a 52-week low of A$11.535. Nasdaq-listed shares dropped 6–7% in early U.S. trading. The company issued a statement confirming completion of Part 1 enrollment in its ProstACT Global Phase 3 study after market rumors. TLX591 has not received marketing authorization.
17 December 2025
···
1 … 8 9 10 11 12 … 19

Stock Market Today

  • SpaceX Set to Join Nasdaq 100, Potential $4.3 Billion Market Boost for SPCX Stock
    June 28, 2026, 8:05 AM EDT. SpaceX ($SPCX), Elon Musk's aerospace and artificial intelligence firm, will join the Nasdaq 100 index on July 7. Inclusion in this key benchmark, which tracks the largest non-financial companies on the Nasdaq stock exchange, could trigger significant passive buying as index funds adjust holdings. Analysts estimate this shift may inject approximately $4.3 billion of demand into SPCX stock. This move underscores SpaceX's growing market footprint following its direct listing and highlights ongoing investor interest in the aerospace and technology sectors.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 8:12 AM EDT SpaceX Set to Join Nasdaq 100, Potential $4.3 Billion Market Boost for SPCX Stock June 28, 2026, 8:05 AM EDT. SpaceX ($SPCX), Elon Musk’s aerospace and artificial intelligence firm, will join the Nasdaq 100 index on July 7. Inclusion in this key benchmark, which tracks the largest non-financial companies on the Nasdaq stock exchange, could trigger significant passive buying as index funds adjust holdings. Analysts estimate this shift may inject approximately $4.3 billion of demand into SPCX stock. This move underscores SpaceX’s growing market footprint
Go toTop